|
(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid Suppliers list
|
(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid manufacturers
- Resolvin D1
-
- $1098.00
-
2026-08-30
- CAS:872993-05-0
- Purity:
- Supply Ability: 10g
- Resolvin D1
-
- $1098.00
-
2026-04-21
- CAS:872993-05-0
- Purity:
- Supply Ability: 10g
|
| | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid Basic information |
| Product Name: | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid | | Synonyms: | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid;(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID;resolvin D1, CID73755062;OIWTWACQMDFHJG-CCFUIAGSSA-N;Resolvin D1 Exclusive;4,9,11,13,15,19-Docosahexaenoic acid, 7,8,17-trihydroxy-, (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-;Resolvin D1 MaxSpec? Standard;Resolvin D1,Resolvin D-1 | | CAS: | 872993-05-0 | | MF: | C22H32O5 | | MW: | 376.49 | | EINECS: | | | Product Categories: | | | Mol File: | 872993-05-0.mol |  |
| | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid Chemical Properties |
| Boiling point | 609.240±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.102±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -80°C,protect from light | | solubility | DMF: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 0.05 mg/ml | | form | Liquid | | pka | 4.579±0.10(predicted) | | color | Colorless to light yellow |
| | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid Usage And Synthesis |
| Uses | Resolvin D1 is used to protect against hepatic injury and heart failure, specifically in rats. Also used as a means to attenuate the inflammatory reaction. | | in vivo | Resolvin D1 (RvD1) (100-1000 ng; i.p.; daily on days 10) improves RA (rheumatoid arthritis) clinical endpoints in arthritic mice[3]. | Animal Model: | 18-20g thirty 8-week-old female DBA/1J mice (collagen antibody-induced arthritis (CAIA))[3] | | Dosage: | 100, 500, and 1000ng (or 1000 ng, daily on days 4-10) | | Administration: | i.p. injection; daily on days 10 | | Result: | Exhibit a reduced arthritic score. |
| | IC 50 | Human Endogenous Metabolite |
| | (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid Preparation Products And Raw materials |
|